Boston Partners’s RxSight RXST Stock Holding History

Boston Partners’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,436	Closed	-$589K	–	750
2023 Q2	$589K	Sell	20,436 -6,550	-24%	-$146K	﹤0.01%	602
2023 Q1	$450K	Buy	26,986 +2,669	+11%	+$37.7K	﹤0.01%	610
2022 Q4	$308K	Buy	24,317 +2,795	+13%	+$34K	﹤0.01%	643
2022 Q3	$258K	Buy	21,522 +2,844	+15%	+$39.1K	﹤0.01%	664
2022 Q2	$263K	Buy	18,678 +3,493	+23%	+$46.1K	﹤0.01%	661
2022 Q1	$188K	Hold	15,185	–	–	﹤0.01%	684
2021 Q4	$171K	Buy	+15,185	New	+$183K	﹤0.01%	673

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $4.41B AUM 90.53% 1-Year Est. Return

Boston Partners's RXST Position: Q3 2023 in Review

Boston Partners sold out of RxSight (RXST) in Q3 2023, closing a stake of 20,436 shares — an estimated $589K sold.

Boston Partners first reported a position in RXST in Q4 2021 and held it in 7 quarters. The position peaked at $589K in Q2 2023. 128 funds tracked by Wall St. Rank hold RXST as of Q3 2023.

Boston Partners reported no remaining RxSight position as of Q3 2023 after selling out during the quarter.
Boston Partners sold 20,436 RxSight shares in Q3 2023, an estimated $589K.
Boston Partners first reported a position in RxSight in Q4 2021 and held it in 7 quarters.
Boston Partners's RxSight position peaked at $589K in Q2 2023.
128 funds tracked by Wall St. Rank held RxSight as of Q3 2023.

Based on Boston Partners's 13F filing for Q3 2023, filed 8 Nov 2023.